# The Efficacy, Safety, and Immunogenicity Study Comparing an Insulin Glargine Biosimilar Sansulin Log-G to Lantus

> **NCT04591457** · PHASE2 · UNKNOWN · sponsor: **Indonesia University** · enrollment: 120 (estimated)

## Conditions studied

- Diabetes Mellitus

## Interventions

- **DRUG:** Insulin Glargine Sansulin
- **DRUG:** Insulin Glargine Pen Injector [Lantus]

## Key facts

- **NCT ID:** NCT04591457
- **Lead sponsor:** Indonesia University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-10
- **Primary completion:** 2021-08
- **Final completion:** 2021-08
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2020-10-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04591457

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04591457, "The Efficacy, Safety, and Immunogenicity Study Comparing an Insulin Glargine Biosimilar Sansulin Log-G to Lantus". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04591457. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*